geriatrРоссийский журнал гериатрической медициныRussian Journal of Geriatric Medicine2686-86362686-8709Сайт издателя10.37586/2686-8636-2-2021-201-208geriatr-178Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESПервые результаты работы регистра пациентов с остеопорозом, включенных в службы профилактики повторных переломовFirst results of the register of patients with osteoporosis included in the secondary fracture prevention serviceshttps://orcid.org/0000-0002-7856-1567БеловаК. Ю.BelovaK. Yu.

Белова Ксения Юрьевна - доктор медицинских наук, заведующая областным лечебно-диагностическим центром остеопороза, Клиническая больница скорой медицинской помощи имени Н.В. Соловьева; доцент кафедры терапии имени профессора Е.Н. Дормидонтова ЯГМУ Минздрава России.

Ярославль.

Тел.: +7(905)633-21-35

Belova Ksenia Yu. - MD, PhD, Head of Regional diagnostics and Treatment Osteoporosis Centre, Soloviev A&E Clinical Hospital; assistant professor, Internal Diseases Department, named after prof. Dormidontov, Yaroslavl State Medical University.

Yaroslavl.

Tel.: +7(905)633-21-35

ksbelova@mail.ruhttps://orcid.org/0000-0003-2998-0893БубликЕ. В.BublikE. V.

Бублик Евгения Викторовна - доктор медицинских наук, врач-эндокринолог отделения эндокринологии, Центральная клиническая больница с поликлиникой при Управлении делами Президента Российской Федерации.

Москва.

Тел.: +7(926)160-43-24

Bublik Yevgnya V. - MD, PhD, endocrinologist of Endocrinology Department, Federal State Budgetary «Central clinical hospital with outpatient health center» of the Business Administration for the President of the Russian Federation.

Moscow.

Tel..: +7(926)160-43-24

evb@mail.ruhttps://orcid.org/0000-0002-6689-6941ГладковаЕ. Н.GladkovaE. N.

Гладкова Елена Николаевна - доктор медицинских наук, ассистент кафедры семейной медицины СЗГМУ им. И.И. Мечникова МЗ РФ; заведующая организационно-методическим и статистическим отделом, Клиническая ревматологическая больница № 25.

Санкт-Петербург.

Тел.: +7(982)651-44-04; +7(812)670-11-75

Gladkova Elena N. - MD, PhD, assistant of Family Medicine Department of the North-Western state medical University named after I.I. Mechnikov of the Russian Federation Ministry of Healthcare; Head of organizational-methodological and statistical Department of the Clinical rheumatology hospital № 25.

Sankt-Peterburg.

Tel.: +7(982)651-44-04; +7(812)670-11-75

gen4605@mail.ruГорджеладзеХ. Г.GordjeladzeH. G.

Горджеладзе Хатиа Геннадиевна - врач-ревматолог отделения плановой консультативной помощи с лечебно-диагностическим центром остеопороза , Клиническая больница скорой медицинской помощи имени Н.В. Соловьева.

Ярославль.

Тел.: +7(4852)28-30-55

Gordjeladze Hatia G. - MD, rheumatologist of the Department of planned consultative care with the osteoporosis treatment and diagnostic center, Soloviev A&E Clinical Hospital.

Yaroslavl.

Tel.: +7(4852)28-30-55

khatia911@gmail.comhttps://orcid.org/0000-0001-7891-6850ДудинскаяЕ. Н.DudinskayaE. N.

Дудинская Екатерина Наильевна - доктор медицинских наук, заведующая лабораторией возрастных метаболических эндокринных нарушений РНИМУ им. Н.И. Пирогова Минздрава России, Российский геронтологический научно-клинический центр.

Москва.

Тел.: +7(903)191-46-90

Dudinskaya Ekaterina N. - MD, PhD, Head of age-related endocrine and metabolic disorders laboratory, Pirogov National Research Medical University, Russian Gerontology Research and Clinical Centre.

Moscow.

Tel.: +7(903)191-46-90

katharina.gin@gmail.comhttps://orcid.org/0000-0001-6418-7060ЛадыгинаД. О.LadyginaD. O.

Ладыгина Дарья Олеговна - доктор медицинских наук, Центральная клиническая больница с поликлиникой при Управлении делами Президента Российской Федерации.

Москва.

Тел.: +7(916)805-00-05

Ladygina Daria O. - MD, PhD, Federal State Budgetary «Central clinical hospital with outpatient health center» of the Business Administration for the President of the Russian Federation.

Moscow.

Tel.: +7(916)805-00-05

ladygina.do@gmail.comМорозоваМ. С.MorozovaM. S.

Морозова Марина Сергеевна - врач-ревматолог отделения плановой консультативной помощи с лечебно-диагностическим центром остеопороза, Клиническая больница скорой медицинской помощи имени Н.В. Соловьева.

Ярославль.

Тел.: +7(4852)28-30-55

Morozova Marina S. - MD, rheumatologist of the department of planned consultative care with the osteoporosis treatment and diagnostic center, Soloviev A&E Clinical Hospital.

Yaroslavl.

Tel.: +7(4852)28-30-55

risha.77@bk.ruhttps://orcid.org/0000-0002-3022-4166ПоляковаЮ. В.PolyakovaYu. V.

Полякова Юлия Васильевна - доктор медицинских наук, заведующая консультативно-диагностическим отделением, научный сотрудник лаборатории методов лечения и профилактики заболеваний суставов, НИИ КиЭР им. А.Б. Зборовского.

Волгоград.

Тел.: +7(8442)78-90-98, +7(909)377-53-54

Polyakova Yulia V. - MD, PhD, Head of the Consultative and Diagnostic department, researcher of the laboratory of methods of treatment and prevention of joint diseases, Zborovsky Research Institute of Clinical and Experimental Rheumatology.

Volgograd.

Tel.: +7(8442)78-90-98, +7(909)377-53-54

jpolyakova@yandex.ruhttps://orcid.org/0000-0002-0965-6060СивордоваЛ. Е.SivordovaL. E.

Сивордова Лариса Евгеньевна - доктор медицинских наук, ведущий научный сотрудник лаборатории методов лечения и профилактики заболеваний суставов, НИИ КиЭР им. А.Б. Зборовского.

Волгоград.

Тел.: +7(8442)78-90-98, +7(902)095-09-99

Sivordova Larisa E. - MD, PhD, leading researcher of the laboratory of methods of treatment and prevention of joint diseases Federal State Budgetary Institution «Zborovsky Research Institute of Clinical and Experimental Rheumatology».

Volgograd.

Tel.: +7(8442)78-90-98, +7(902)095-09-99

seeword@mail.ruhttps://orcid.org/0000-0001-5594-8526ТанаевВ. Г.TanaevV. G.

Танаев Вячеслав Генрихович - ревматолог, консультативно-диагностический центр профилактики остеопороза, СПб Клиническая ревматологическая больница № 25.

Санкт-Петербург.

Тел.: +7(812)246-73-39

Tanaev Vyacheslav G. - MD, rheumatologist of the Consultative and Diagnostic Center for Osteoporosis Prevention of the Clinical Rheumatology Hospital № 25.

Sankt-Peterburg.

Tel.: +7(812)246-73-39

info@policlinica24.ruhttps://orcid.org/0000-0002-0143-0614ЛеснякО. М.LesnyakO. M.

Лесняк Ольга Михайловна - доктор медицинских наук, профессор, профессор кафедры семейной медицины СЗГМУ им. И.И. Мечникова Минздрава России; заведующая консультативно-диагностическим центром профилактики остеопороза, Клиническая ревматологическая больница № 25.

Санкт-Петербург.

Тел.: +7(965)814-07-01

Lesnyak Olga M. - MD, PhD, Professor, Professor of the Department of Family Medicine North-Western State Medical University named after I.I. Mechnikov of the Russian Federation Ministry of Healthcare; Head of the Consultative and Diagnostic Center for the Prevention of Osteoporosis of the Clinical Rheumatology Hospital № 25.

Sankt-Peterburg.

Tel.: +7(965)814-07-01

olga.m.lesnyak@yandex.ruЯрославский государственный медицинский университет МЗ РФ; Клиническая больница скорой медицинской помощи имени Н.В. СоловьеваРоссияYaroslavl State Medical University; Solovyov A&E Clinical HospitalRussian FederationЦентральная клиническая больница с поликлиникой при Управлении делами Президента Российской ФедерацииРоссияCentral clinical hospital with outpatient health center of the Business Administration for the President of the Russian FederationRussian FederationСеверо-западный государственный медицинский университет им. И.И. Мечникова; Клиническая ревматологическая больница № 25РоссияNorth-Western state medical University named after I.I. Mechnikov; Clinical rheumatology hospital № 25Russian FederationЯрославский государственный медицинский университет МЗ РФ; Клиническая больница скорой медицинской помощи имени Н.В. СоловьеваРоссияSolovyov A&E Clinical HospitalRussian FederationРоссийский национальный исследовательский медицинский университет имени Н.И. Пирогова Минздрава РоссииРоссияPirogov National Research Medical University, Russian Gerontology Research and Clinical CentreRussian FederationКлиническая больница скорой медицинской помощи имени Н.В. СоловьеваРоссияSolovyov A&E Clinical HospitalRussian FederationНаучно-исследовательский институт клинической и экспериментальной ревматологии имени А.Б. ЗборовскогоРоссияZborovsky Research Institute of Clinical and Experimental RheumatologyRussian FederationКлиническая ревматологическая больница № 25РоссияClinical rheumatology hospital № 25Russian Federation20210108202102211218Copyright © Белова К.Ю., Бублик Е.В., Гладкова Е.Н., Горджеладзе Х.Г., Дудинская Е.Н., Ладыгина Д.О., Морозова М.С., Полякова Ю.В., Сивордова Л.Е., Танаев В.Г., Лесняк О.М., 20212021Белова К.Ю., Бублик Е.В., Гладкова Е.Н., Горджеладзе Х.Г., Дудинская Е.Н., Ладыгина Д.О., Морозова М.С., Полякова Ю.В., Сивордова Л.Е., Танаев В.Г., Лесняк О.М.Belova K.Y., Bublik E.V., Gladkova E.N., Gordjeladze H.G., Dudinskaya E.N., Ladygina D.O., Morozova M.S., Polyakova Y.V., Sivordova L.E., Tanaev V.G., Lesnyak O.M.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.geriatr-news.com/jour/article/view/178Актуальность

Актуальность. Для снижения числа остеопоротических переломов в мире в последние годы создаются службы профилактики повторных переломов (СППП). В России с 2019 года начата разработка регистра пациентов, включенных в СППП, который был назван «Прометей».

Материалы и методы

Материалы и методы. Создана информационная система для хранения, поиска и обработки информации, разработана регистрационная карта. В ведении регистра принимают участие 6 СППП. На 10.03.2021 в регистр внесены данные по 387 пациентам.

Результаты

Результаты. Среди включенных пациентов 46,25% получили перелом проксимального отдела бедренной кости, 20,41% — тел позвонков и 16,80% — проксимального отдела плечевой кости, у остальных отмечены переломы других локализаций. Оценка риска переломов выполнена у всех больных. Высокий риск основных остеопоротических переломов по FRAX определен у 160 (43,24%) человек. Двухэнергетическая рентгеновская абсорбциометрия (DXA) выполнена у 152 (39,28%) пациентов, остеопороз выявлен у 103 (67,76%) больных, остеопения — у 42 (27,63%) пациентов. Оценка риска падений выполнена у 100% включенных пациентов, риск падений определен как высокий у 343 (88,63%) больных. Оценка различных лабораторных параметров для поиска причин вторичного остеопороза выполнена у большинства пациентов. После консультации врача СППП антиостеопоротические препараты назначены 241 (64,27%) человеку. Среди остальных у 70 (52,24%) больных выявлены противопоказания и 31 (23,13%) человек нуждался в проведении дальнейшего обследования.

Выводы

Выводы. Таким образом, использование регистра позволяет оценить все основные разделы организации помощи внутри СППП и сравнить их с международными стандартами для выявления «пробелов» и совершенствования работы службы.

Background

Background. To reduce the number of osteoporotic fractures in the world in recent years, — Fracture Liaison Service has been created. Since 2019, the development of a register of patients included in the Secondary Fracture Prevention named «Prometheus» has begun in Russia.

Materials and methods

Materials and methods. An information system for storing, searching and processing information has been created, and a registration card has been developed. Six FLS participate in the register management. As of 10.03.2021, data on 387 patients were introduced in the register.

Results

Results. Among the included patients, 46.25% received a fracture of the proximal femur, 20.41% — of the vertebral bodies and 16.80% of the proximal humerus, the rest had fractures of other localizations. The risk of fractures was assessed in all patients. A high risk of major osteoporotic fractures according to FRAX was determined in 160 (43.24%) people. Two-energy X-ray absorptiometry (DXA) was performed in 152 (39.28%) patients, and osteoporosis was detected in 103 (67.76%), osteopenia — in 42 (27.63%) patients. The risk of falls was assessed in 100% of the included patients, and the risk of falls was determined to be high in 343 (88.63%) patients. Evaluation of various laboratory parameters to find the causes of secondary osteoporosis was performed in most patients. After consultation with the FLS doctor, anti-osteoporotic drugs were prescribed to 241 (64.27%) people. Among the rest, 70 (52.24%) patients had contra-indications and 31 (23.13%) people needed further examination.

Conclusions

Conclusions. Thus, the use of the register allows you to evaluate all the main sections of the organization of assistance within the FLS and compare them with international standards to identify «gaps» and improve the work of the service.

служба профилактики повторных переломовнизкоэнергетические переломыFRAXриск паденийрегистрfracture liaison servicefragility fracturesFRAXrisk of fallsregisterReferencesЛесняк О.М. Аудит состояния проблемы остеопороза в странах Восточной Европы и Центральной Азии в 2010 году. Остеопороз и остеопатии. 2011; 2: 3-6.Lesnyak OM. Audit sostoyaniya problemy osteoporoza v stranah Vostochnoj Evropy i Central'noj Azii v 2010 godu. Osteoporoz i osteopatii. 2011; 2: 3-6.Ganda K., Puech M., Chen J.S. et al. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporos Int. 2013; 24(2): 349-406. https://doi.org/10.1007/s00198-012-2090-yGanda K., Puech M., Chen J.S. et al. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporos Int. 2013; 24(2): 349-406. https://doi.org/10.1007/s00198-012-2090-yJohnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17: 1726-1733. https://doi.org/10.1007/s00198-006-0172-4Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17: 1726-1733. https://doi.org/10.1007/s00198-006-0172-4Papaioannou A., Kennedy C.C., Ioannidis G. et al. The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int. 2008; 19: 581-587. https://doi.org/10.1007/s00198-007-0483-0Papaioannou A., Kennedy C.C., Ioannidis G. et al. The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int. 2008; 19: 581-587. https://doi.org/10.1007/s00198-007-0483-0Lesnyak O., Ershova O., Belova K., et al. Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Arch Osteoporos. 2012; 7 (1-2): 67-73. https://doi.org/10.1007/s11657-012-0082-3Lesnyak O., Ershova O., Belova K., et al. Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Arch Osteoporos. 2012; 7 (1-2): 67-73. https://doi.org/10.1007/s11657-012-0082-3Kanis J.A., Johnell O., De Laet C., et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004; 35 (2): 375382. https://doi.org/10.1016/j.bone.2004.03.024Kanis J.A., Johnell O., De Laet C., et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004; 35 (2): 375382. https://doi.org/10.1016/j.bone.2004.03.024Klotzbuecher C.M., Ross P.D., Landsman P.B., Abbott 3rd T.A., Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000; 15 (4): 721-739. https://doi.org/10.1359/jbmr.2000.15.4.721Klotzbuecher C.M., Ross P.D., Landsman P.B., Abbott 3rd T.A., Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000; 15 (4): 721-739. https://doi.org/10.1359/jbmr.2000.15.4.721Port L., Center J., Briffa N.K. et al. Osteoporotic fracture: missed opportunity for intervention. Osteoporos Int. 2003; 14 (9): 780-784. https://doi.org/10.1007/s00198-003-1452-xPort L., Center J., Briffa N.K. et al. Osteoporotic fracture: missed opportunity for intervention. Osteoporos Int. 2003; 14 (9): 780-784. https://doi.org/10.1007/s00198-003-1452-xMcLellan A., Reid D., Forbes K. et al. Effectiveness of Strategies for the Secondary Prevention of Osteoporotic Fractures in Scotland (CEPS 99/03). NHS Quality Improvement Scotland. 2004.McLellan A., Reid D., Forbes K. et al. Effectiveness of Strategies for the Secondary Prevention of Osteoporotic Fractures in Scotland (CEPS 99/03). NHS Quality Improvement Scotland. 2004.Edwards B.J., Bunta A.D., Simonelli C., Bolander M., Fitzpatrick L.A. Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Relat Res. 2007; 461: 226-230. https://doi.org/10.1097/blo.0b013e3180534269Edwards B.J., Bunta A.D., Simonelli C., Bolander M., Fitzpatrick L.A. Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Relat Res. 2007; 461: 226-230. https://doi.org/10.1097/blo.0b013e3180534269Wells G.A., Cranney A., Peterson J., et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; (1): CD001155. https://doi.org/10.1002/14651858.cd001155.pub2Wells G.A., Cranney A., Peterson J., et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; (1): CD001155. https://doi.org/10.1002/14651858.cd001155.pub2Palacios S., Kalouche-Khalil L., Rizzoli R., et al. Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis. Climacteric. 2015; 18(6): 805-12. https://doi.org/10.3109/13697137.2015.1045484Palacios S., Kalouche-Khalil L., Rizzoli R., et al. Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis. Climacteric. 2015; 18(6): 805-12. https://doi.org/10.3109/13697137.2015.1045484Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434-41. https://doi.org/10.3171/foc.2001.11.2.8Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434-41. https://doi.org/10.3171/foc.2001.11.2.8Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357(18): 1799-809. https://doi.org/10.1056/nejmoa074941Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357(18): 1799-809. https://doi.org/10.1056/nejmoa074941Akesson K., Marsh D., Mitchell P.J. et al.: IOF Fracture Working Group. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int. 2013; 24 (8): 2135-2152. https://doi.org/10.1007/s00198-013-2348-zAkesson K., Marsh D., Mitchell P.J. et al.: IOF Fracture Working Group. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int. 2013; 24 (8): 2135-2152. https://doi.org/10.1007/s00198-013-2348-zHagino H., Sawaguchi T., Endo N., et al. The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int. 2012; 90: 14-21. https://doi.org/10.1007/s00223-011-9545-6Hagino H., Sawaguchi T., Endo N., et al. The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int. 2012; 90: 14-21. https://doi.org/10.1007/s00223-011-9545-6Ganda K., Mitchell P.J., Seibel M.J. Chapter 3 — Models of Secondary Fracture Prevention: Systematic Review and Meta-analysis of Outcomes. Secondary Fracture Prevention. An International Perspective. 2019. P. 33-62. https://doi.org/10.1016/b978-0-12-813136-7.00003-xGanda K., Mitchell P.J., Seibel M.J. Chapter 3 — Models of Secondary Fracture Prevention: Systematic Review and Meta-analysis of Outcomes. Secondary Fracture Prevention. An International Perspective. 2019. P. 33-62. https://doi.org/10.1016/b978-0-12-813136-7.00003-xMarsh D., Akesson K., Beaton D.E. et al. Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int. 2011; 22: 2051-2065. https://doi.org/10.1007/s00198-011-1642-xMarsh D., Akesson K., Beaton D.E. et al. Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int. 2011; 22: 2051-2065. https://doi.org/10.1007/s00198-011-1642-xEisman J.A., Bogoch E.R., Dell R., et al.. Making the first fracture the last fracture: ASBMR Task Force on Secondary Fracture Prevention. J Bone Miner Res. 2012 Oct; 27(10): 2039-46. https://doi.org/10.1002/jbmr.1698Eisman J.A., Bogoch E.R., Dell R., et al.. Making the first fracture the last fracture: ASBMR Task Force on Secondary Fracture Prevention. J Bone Miner Res. 2012 Oct; 27(10): 2039-46. https://doi.org/10.1002/jbmr.1698International Osteoporosis Foundation. Capture the Fracture: a global campaign to break the fragility fracture cycle — 2012 // International Osteoporosis Foundation: сайт. — Режим доступа: https://www.iofbonehealth.org/capture-fracture-report-2012. — Загл. с экрана.International Osteoporosis Foundation. Capture the Fracture: a global campaign to break the fragility fracture cycle — 2012 // International Osteoporosis Foundation: сайт. — Режим доступа: https://www.iofbonehealth.org/capture-fracture-report-2012. — Загл. с экрана.International Osteoporosis Foundation. Capture the Fracture: break the worldwide fragility fracture cycle — 2012 // International Osteoporosis Foundation: сайт. — Режим доступа: https://www.iofbonehealth.org/capture-fracture. — Загл. с экранаInternational Osteoporosis Foundation. Capture the Fracture: break the worldwide fragility fracture cycle — 2012 // International Osteoporosis Foundation: сайт. — Режим доступа: https://www.iofbonehealth.org/capture-fracture. — Загл. с экранаSale J.E., Beaton D., Posen J., et al. Systematic review on interventions to improve osteoporosis investigation and treatment in fragility fracture patients. Osteoporos Int. 2011; 22: 2067-2082. https://doi.org/10.1007/s00198-011-1544-ySale J.E., Beaton D., Posen J., et al. Systematic review on interventions to improve osteoporosis investigation and treatment in fragility fracture patients. Osteoporos Int. 2011; 22: 2067-2082. https://doi.org/10.1007/s00198-011-1544-yDell R. Fracture prevention in Kaiser Permanente Southern California. Osteoporos Int. 2011; 22 Suppl 3: 457-60. https://doi.org/10.1007/s00198-011-1712-0Dell R. Fracture prevention in Kaiser Permanente Southern California. Osteoporos Int. 2011; 22 Suppl 3: 457-60. https://doi.org/10.1007/s00198-011-1712-0Lih A., Nandapalan H., Kim M., et al. Targeted intervention reduces refracture rates in patients with incident non-vertebral osteoporotic fractures: a 4-year prospective controlled study. Osteoporos Int. 2011; 22(3): 849-58. https://doi.org/10.1007/s00198-010-1477-xLih A., Nandapalan H., Kim M., et al. Targeted intervention reduces refracture rates in patients with incident non-vertebral osteoporotic fractures: a 4-year prospective controlled study. Osteoporos Int. 2011; 22(3): 849-58. https://doi.org/10.1007/s00198-010-1477-xHuntjens K.M., van Geel T.A., van den Bergh J.P., et al. Fracture liaison service: impact on subsequent nonvertebral fracture incidence and mortality. J Bone Joint Surg Am. 2014; 96(4): e29. https://doi.org/10.2106/jbjs.l.00223Huntjens K.M., van Geel T.A., van den Bergh J.P., et al. Fracture liaison service: impact on subsequent nonvertebral fracture incidence and mortality. J Bone Joint Surg Am. 2014; 96(4): e29. https://doi.org/10.2106/jbjs.l.00223Van der Kallen J., Giles M., Cooper K., et al. A fracture prevention service reduces further fractures two years after incident minimal trauma fracture. Int J Rheum Dis. 2014; 17(2): 195-203 https://doi.org/10.1111/1756-185x.12101Van der Kallen J., Giles M., Cooper K., et al. A fracture prevention service reduces further fractures two years after incident minimal trauma fracture. Int J Rheum Dis. 2014; 17(2): 195-203 https://doi.org/10.1111/1756-185x.12101Olenginski T.P., Maloney-Saxon G., Matzko C.K., et al. High-risk osteoporosis clinic (HiROC): improving osteoporosis and postfracture care with an organized, programmatic approach. Osteoporos Int. 2015; 26(2): 801-10 https://doi.org/10.1007/s00198-014-2967-zOlenginski T.P., Maloney-Saxon G., Matzko C.K., et al. High-risk osteoporosis clinic (HiROC): improving osteoporosis and postfracture care with an organized, programmatic approach. Osteoporos Int. 2015; 26(2): 801-10 https://doi.org/10.1007/s00198-014-2967-zGanda K., Schaffer A., Pearson S., Seibel M.J. Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management. Osteoporos Int. 2014; 25 (4): 1345-1355. https://doi.org/10.1007/s00198-013-2610-4Ganda K., Schaffer A., Pearson S., Seibel M.J. Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management. Osteoporos Int. 2014; 25 (4): 1345-1355. https://doi.org/10.1007/s00198-013-2610-4Little E.A., Eccles M.P. A systematic review of the effectiveness of interventions to improve post-fracture investigation and management of patients at risk of osteoporosis. Implement. Sci. 2010; 5: 80. https://doi.org/10.1186/1748-5908-5-80Little E.A., Eccles M.P. A systematic review of the effectiveness of interventions to improve post-fracture investigation and management of patients at risk of osteoporosis. Implement. Sci. 2010; 5: 80. https://doi.org/10.1186/1748-5908-5-80Javaid M.K., Sami A., Lems W. et al. A patient-level key performance indicator set to measure the effectiveness of fracture liaison services and guide quality improvement: a position paper of the IOF Capture the Fracture Working Group, National Osteoporosis Foundation and Fragility Fracture Network. Osteoporosis International. 2020; 31: 1193-1204. https://doi.org/10.1007/s00198-020-05377-1Javaid M.K., Sami A., Lems W. et al. A patient-level key performance indicator set to measure the effectiveness of fracture liaison services and guide quality improvement: a position paper of the IOF Capture the Fracture Working Group, National Osteoporosis Foundation and Fragility Fracture Network. Osteoporosis International. 2020; 31: 1193-1204. https://doi.org/10.1007/s00198-020-05377-1Gittoes N., McLellan A.R., Cooper A. et al. Effective Secondary Prevention of Fragility Fractures: Clinical Standards for Fracture Liaison Services. Camerton: National Osteoporosis Society. 2015.Gittoes N., McLellan A.R., Cooper A. et al. Effective Secondary Prevention of Fragility Fractures: Clinical Standards for Fracture Liaison Services. Camerton: National Osteoporosis Society. 2015.Shipman K.E., Stammers J., Doyle A., Gittoes N. Delivering a quality-assured fracture liaison service in a UK teaching hospital-is it achievable? Osteoporos Int. 2016. https://doi.org/10.1007/s00198-016-3639-yShipman K.E., Stammers J., Doyle A., Gittoes N. Delivering a quality-assured fracture liaison service in a UK teaching hospital-is it achievable? Osteoporos Int. 2016. https://doi.org/10.1007/s00198-016-3639-yRoyal College of Physicians Falls and Fragility Fracture Audit Programme. Fracture Liaison Service Database (FLS-DB) facilities audit. FLS breakpoint: opportunities for improving patient care following a fragility fracture. London: 2016.Royal College of Physicians Falls and Fragility Fracture Audit Programme. Fracture Liaison Service Database (FLS-DB) facilities audit. FLS breakpoint: opportunities for improving patient care following a fragility fracture. London: 2016.Gallacher S., Alexander S., Beswetherick Will Carr N. et al. Effective Secondary Prevention of Fragility Fractures: Clinical Standards for Fracture Liaison Services. Royal Osteoporosis Society. 2019.Gallacher S., Alexander S., Beswetherick Will Carr N. et al. Effective Secondary Prevention of Fragility Fractures: Clinical Standards for Fracture Liaison Services. Royal Osteoporosis Society. 2019.National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women: NICE Technology Appraisal Guidance 161. 2010.National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women: NICE Technology Appraisal Guidance 161. 2010.Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я. с соавт. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы Эндокринологии. 2017; 63 (6): 392-426 https://doi.org/10.14341/probl2017636392-426Mel'nichenko GA, Belaya ZhE, Rozhinskaya LYа s soavt. Federal'nye klinicheskie rekomendacii po diagnostike, lecheniyu i profilaktike osteoporoza. Problemy Endokrinologii, 2017; 63 (6): 392-426 https://doi.org/10.14341/probl2017636392-426

The authors declare that there are no conflicts of interest present.